Abstract
Rationale COVID-19 have deprived many lives in Wuhan, China and caused global concerns. Few studies focused on clinical characteristics non-survivors hospitalized with COVID-19.
Objectives We aimed to clarify the clinical characteristics of died patients with COVID-19 and tracked the causes of the rapid disease progression and death.
Methods 101 non-surviving patients with confirmed COVID-19 were included in this retrospective study. Clinical data were collected and compared between non-survivors who died within 3 days and after 3 days of admission. Multivariable regression analysis was used to analyze risk factors associated with rapid disease progression and death.
Measurements and Main Results Among included patients, median age was 71 years (IQR, 59-80), 60 (59.41%) were men. 82 (81.19%) had one or more comorbidities including hypertension (59 [58.42%]), diabetes (22 [21.78%]) etc. 100 (99.01%) suffered respiratory failure, 53 (52.48%) developed acute cardiac injury, acute kidney and liver injury occurred in 23 (22.77%) and 18 (17.82%) patients, respectively. Multivariable regression analysis showed that elevated high sensitivity troponin I (OR 2.68, 95%CI 1.31-5.49, P=0.007), neutrophils (OR 1.14, 95%CI 1.01-1.28, P=0.033) and depressed oxygen saturation (OR 0.94, 95%CI 0.89-0.99, P=0.027) on admission were associated with rapid death of patients with COVID-19.
Conclusions Older patients (>70 years) with comorbidities had a steeply increased risk of death with COVID-19. Respiratory failure, acute cardiac and kidney injury played a crucial role in the death of patients. Elevated high sensitivity troponin, neutrophils and depressed oxygen saturation predicted the rapid death of patients.
Scientific Knowledge on the Subject COVID-19 have deprived many lives and caused global concerns. We searched PubMed for articles published up to Mar 10, 2020, using the keywords “2019 novel coronavirus”, “2019-nCoV”, “COVID-19”, or “SARS-CoV-2”. We identified that few studies focused on clinical characteristics of non-survivors with COVID-19.
What This Study Adds to the Field We reported the demographic and clinical characteristics of 101 non-surviving hospitalized patients with COVID-19. This study showed that older patients (>70 years) with comorbidities had a steeply increased risk of death when they suffered COVID-19. Besides, respiratory failure, acute cardiac and kidney injury played a crucial role in the rapid death of patients. Furthermore, multivariable regression analysis revealed elevated levels of high sensitivity troponin I, neutrophils and depressed oxygen saturation were associated with increased odds of rapid death of patients with COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Dr. Weixing Wang serves as the corresponding author to communicate with editors. Weixing Wang, MD, Department of General Surgery, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan 430060, China., Phone: +86 13907141893, E-mail: sate.llite{at}163.com
Funding: This study was funded by National Natural Science Foundation of China (No.81800574; No.81870442; No.81700567).
Data Availability
all original data were saved in Renmin Hospital of Wuhan University, Wuhan, China